Loading clinical trials...
Loading clinical trials...
The primary purpose of the proposed study is to characterize the oxidative stress and inflammatory cytokine status in UCD during baseline and decompensated states.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Mark Batshaw
Collaborators
NCT06805695 · Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, and more
NCT06953505 · Urea Cycle Disorders, Organic Acidemias, and more
NCT01257737 · Urea Cycle Disorders
NCT00947544 · Urea Cycle Disorders
NCT00947297 · Urea Cycle Disorders
University of California, Los Angeles
Los Angeles, California
The Children's Hospital, Aurora
Aurora, Colorado
Children's National Medical Center
Washington D.C., District of Columbia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions